KOMET: an unblinded, randomised, two parallel-group, stratified trial comparing the effectiveness of levetiracetam with controlled-release carbamazepine and extended-release sodium valproate as monotherapy in patients with newly diagnosed epilepsy.
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
To compare the effectiveness of levetiracetam (LEV) with extended-release sodium valproate
(VPA-ER) and controlled-release carbamazepine (CBZ-CR) as monotherapy in patients
with newly diagnosed epilepsy.